Skip to main content
. 2016 Nov 9;9:6843–6855. doi: 10.2147/OTT.S117743

Figure 3.

Figure 3

Figure 3

Effects of drug combinations on signaling pathways in mutant KRAS cells.

Notes: H358, A549, and PLC/PRF5 cells were treated for 96 hours with gefitinib (H358: 0.2 µmol/L, A549 and PLC/PRF5: 3 µmol/L), sorafenib (3 µmol/L), vorinostat (2 µmol/L), OSI-906 (H358: 1 µmol/L, A549 and PLC/PRF5: 3 µmol/L), alone or combined as indicated. (A, B, D) Total cell lysates were collected and subjected to Western blotting. (C) The percentage of apoptosis was scored and expressed as the mean ± standard deviation.